Clinical Trials Logo

Filter by:
NCT ID: NCT03380559 Completed - Epicondylitis Clinical Trials

A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis

EPITOX
Start date: April 19, 2019
Phase: Phase 3
Study type: Interventional

The study aims to demonstrate that intramuscular injection of botulinum toxin with a paralyzing dose coupled with subcutaneous injection of corticoid has greater efficacy than corticoid injection only or toxin injection only for treating lateral epicondylitis in reducing pain at 6 months. As secondary objectives, the study aims to - demonstrate improvement of quality of patient's life and positive effect on their resuming to professional activities or sportive activities. - evaluate tolerance of treatment by grip strength measurement and adverse event collection.

NCT ID: NCT03380247 Completed - Pain Clinical Trials

Multimodal Oral Analgesia for Trauma in the Emergency Department

START
Start date: October 12, 2017
Phase:
Study type: Observational

The prevalence of pain in the emergency department is estimated between 60% and 78%. However, many studies reported oligo analgesia in about half of patient admitted to the emergency department. The delay before effective analgesia is one of the main causes of oligoanalgesia. The use of nurse-directed protocol allows the administration of analgesic upon admission to the emergency department. Nevertheless the need of intravenous access may delay analgesia. The use of oral form analgesics even with immediate release does not allow effective analgesia before 20 min. Pain management protocol in the emergency reception desk of CHU Grenoble Alpes (CHUGA) includes paracetamol that can be combined with oxycodone tablets depending on the pain intensity. For any mono traumatized it is possible to associate self-administer methoxyflurane inhaler. The pain management protocol is already used in the emergency reception desk of CHU Grenoble Alpes.The different analgesics( paracetamol,oral oxycodone, methoxyflurane) are already administered as part of routine care.The use of these different analgesics means would allow a rapid and adapted effectiveness to the pain intensity. However, there are no data on the efficacy and acceptability of such an early multimodal analgesia protocol in the emergency department.

NCT ID: NCT03379961 Completed - Clinical trials for Socialised Disturbance of Conduct

Identification and Research of Impacts of Social Categorization Process in Nurse Triage (SOCIAL SORTING)

SOCIALSORTING
Start date: January 10, 2018
Phase:
Study type: Observational [Patient Registry]

Social Sorting is a: non interventional, observational, qualitative and multicenter research. It investigates three French emergency units in three French centers (UH of Angers, H of Le Mans, H of Laval). It is a research based on nursing sciences and social-psychology and it proposes to study the process of social categorization that intervenes during triage nursing. The process of social categorization has developped since the beginning of XX century (LIPPMANN, in 1922, in United States, he gave the first definition of stereotype// DURKHEIM, in France described step by step the individuals and the collectives representations. During XX century the social psychology developed a lot of studs about group dynamics (social categorization, influence phenomenon, conspiracy theories,...) within several domains : industry, politics, public services as police, social units,... and also in healthcare (but always about a social categorisation in particular and often with a limited study of impacts). Social Sorting includes all social categorization as possible and search to do a scientific evaluation of their impact.

NCT ID: NCT03379831 Completed - Clinical trials for Congenital Heart Disease

Correlation Between Quality of Life and Aerobic Physical Fitness of Patients With a Systemic Right Ventricle

Start date: January 12, 2018
Phase:
Study type: Observational

Congenital heart disease (CHD) is the most common congenital malformations. The right ventricle in the sub-aortic position, or "systemic right ventricle" is one of these complex cardiac diseases. Several studies show that adults with CHD and especially systemic right ventricle have reduced exercise capacity. In addition, studies have shown that there is a correlation between alteration of aerobic physical capacity and alteration of right ventricular systolic function. Understanding and assessing the determinants of the physical capacity of patients with systemic right ventricles and evaluating their quality of life could allows us to improve their therapeutic management and also to expand patient indications to a program cardiac rehabilitation. This can benefit them on their exercise capacity, their tolerance to exercise and their quality of life. The aim is to study the correlation between the quality of life and the aerobic physical fitness of patients with a systemic right ventricle and to determine the clinical and paraclinical parameters that have an impact on the aerobic physical fitness of these patients. The quality of life of patients with a systemic right ventricle will be compared to that of the general population.

NCT ID: NCT03379727 Completed - Clinical trials for Acute Myeloid Leukemia

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Start date: February 13, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who were eligible for standard induction and consolidation

NCT ID: NCT03379675 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Start date: February 6, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams [mg] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.

NCT ID: NCT03379285 Completed - Clinical trials for Gastro Intestinal Bleeding

Management of Digestive Haemorrhaging In CHRU of Brest During 2009 and 2014

HDréa
Start date: October 3, 2016
Phase: N/A
Study type: Observational

Gastro intestinal (GI) bleeding is relatively frequent and may lead to intensive care unit admission. Although a restrictive strategy for red blood cell transfusion is supported by a large randomized controlled trial literature, less is known about the impact of transfusion strategy of other blood components and administration of anti fibrinolytic on clinical outcomes. This study aims to identify parameters that may be associated with the risk of further bleeding in patients admitted to ICU for GI bleeding.

NCT ID: NCT03378947 Completed - Clinical trials for To Characterize and Compare Clinical, Pathological and Molecular Features

EBV-associated Diffuse Large B Cell Lymphoma

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of EBV-related GZL and DLBCL: do they belong to the same entity or to two different subtypes of EBV-related lymphoma ?

NCT ID: NCT03378895 Completed - Obesity Clinical Trials

CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne

CEPPPIA
Start date: December 1, 2017
Phase: N/A
Study type: Interventional

The state of health in France appears to be good with regard to major indicators such as life expectancy at birth. However, France is characterized by a high standardized rate of premature mortality (deaths occurring before the age of 65) in comparison with other European countries, with geographical disparities. Between 2006 and 2010, the standardized rate of premature mortality was higher in Auvergne than the national average. Chronic diseases such as cardiovascular diseases, cancers and / or metabolic diseases (including diabetes and obesity) are the main causes of these premature deaths. These diseases have several causes: they depend on the genetic heritage, the way of life and the environment. Family history is a known risk factor for these chronic diseases. Eating habits, insufficient physical activity or physical inactivity, excessive drinking and smoking which promote the occurrence of these chronic diseases are the main risk factors that we can modify. Preventive measures are known and are regularly the subject of public health plans and awareness campaigns targeting lifestyles modification of the populations. These prevention campaigns affect entire population, while the risk factors for chronic diseases are different from one to another, this encourages personalization of preventive measures. The CEPPPIA pilot study falls within this framework and aims to evaluate the feasibility of setting up an individualized prevention program on the modification of health behaviors among people aged 35 to 55, who has a moderate risk of developing chronic diseases and residing in Auvergne territory.

NCT ID: NCT03378453 Completed - Narcolepsy Clinical Trials

Narcolepsy Protect Against Alzheimer's Disease?

PROTECMAN
Start date: April 7, 2016
Phase: N/A
Study type: Interventional

Links between orexin and amyloid processes have been underlined recently. During the Alzheimer's process an upregulation of the orexin mechanism has been observed. The pathophysiological mechanism of narcolepsy type 1 is linked to orexin deficiency. Thus, the investigators hypothesized that patients with narcolepsy may be protected from amyloid brain lesions, hallmarks of the Alzheimer's process. To test this hypothesis, the investigators analyzed the brain amyloid load measured by PET-scan amyloid brain imaging in patients with narcolepsy type 1 compared to controls without cognitive deficits.